Immunogenicity and Safety of Trivalent Inactivated Influenza Vaccine: A Randomized, Double-Blind, Multi-Center, Phase 3 Clinical Trial in a Vaccine-Limited Country

다국어 초록 (Multilingual Abstract)

Influenza vaccines are the primary method for controlling influenza and its complications.
This study was conducted as a phase 3, randomized, double-blind, controlled, multicenter trial at seven university hospitals to evaluate the immunogenicity and safety of an inactivated, split, trivalent influenza vaccine (GC501, Green Cross Corporation, Yongin,Korea), which was newly manufactured in Korea in 2008. Between September 21 and 26,a total of 329 healthy subjects were recruited for the immunogenicity analysis, while 976subjects were enrolled for the safety analysis. The GC501 vaccine met both FDA and EMEA criteria with ≥ 80% of subjects achieving post-vaccination titers ≥ 40 for all three subtypes, even in the elderly. The vaccine was well tolerated with only mild systemic and local adverse events. In summary, GC501 showed excellent immunogenicity and a good safety profile in both young adults and the elderly. The licensure of GC501 might be an important basis in preparation for the future influenza pandemic.

참고문헌 (Reference)

1 박승철, "만성질환자에서 인플루엔자 예방 접종의 효능 분석 : 후향적 환자-대조군 연구" 대한감염학회 36 (36): 207-212, 2004

2 Cheong HJ, "Safety of influenza vaccine" 50 : 267-273, 2007

3 Fedson DS, "Pandemic influenza and the global vaccine supply" 36 : 1552-1561, 2003

4 European Committee for Proprietary Medicinal Products, "Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/ BWP/214/96). London, UK: The Europen Agency for the Evaluation of Medicinal Products; c1997"

5 Song JY, "Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence" ELSEVIER SCI LTD 28 (28): 3929-3935, 2010

6 Wilschut JC, "Influenza. 2nd ed" Elsevier Ltd 117-132, 2006

7 Kee SY, "Influenza vaccine coverage rates and perceptions on vaccination in South Korea" W B SAUNDERS CO LTD 55 : 273-281, 2007

8 Lee JS, "Influenza surveillance in Korea: establishment and first results of an epidemiological and virological surveillance scheme" CAMBRIDGE UNIV PRESS 135 (135): 1117-1123, 2007

9 U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, "Guidance for industry: clinical data needed to support the licensure of trivalent inactivated influenza vaccines; c2006"

10 U.S. Department of Health and Human Services FDA, Center for Biologics Evaluation and Research, "Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. 2007"

11 El Sahly HM, "Clinical data on Fluarix: an inactivated split seasonal influenza vaccine" 7 : 713-719, 2008